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Purpose
The MUC1 tumor-associated antigen is overexpressed in
the majority of human carcinomas and several hematolo-
gic malignancies. Much attention has been paid to the
hypoglycosylated VNTR region of the N-terminus of
MUC1 as a vaccine target, and recombinant viral vector
vaccines are also being evaluated that express the entire
MUC1 transgene. While previous studies have descri-
bed MUC1 as a tumor-associated tissue differentiation
antigen, numerous studies have now determined that
the C-terminus of MUC1 (MUC1-C) is an oncoprotein,
and its expression is an indication of poor prognosis in
numerous tumor types.
Experimental design
We report here the identification of seven potential CD8+
cytotoxic T lymphocyte epitopes of MUC1: five in the C-
terminus and two in the VNTR region, and have identified
enhancer agonist peptides for each of these epitopes.
These epitopes span HLA-A2 and A3 MHC class I alleles,
which encompass two thirds of the population.
Results
The agonist peptides, compared to the native peptides,
more efficiently (a) generate T-cell lines from the peri-
pheral blood mononuclear cells of cancer patients,
(b) enhance the production of IFN-g by peptide-activated
human T cells, and (c) lyse human tumor cell targets in an
MHC-restricted manner.
Conclusions
The agonist epitopes described here can be incorporated
in various vaccine platforms and for ex vivo generation of
human T cells. These studies thus provide the rationale
for the T-cell-mediated targeting of the oncogenic
C-terminus of MUC1, which has been shown to be
an important factor in both drug resistance and poor
prognosis for numerous tumor types.
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